MedTrace Logo

Restylane Defyne for Correction of Chin Retrusion

NCT03597256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-06-12

Study results available
· View outcomes & findings →

Summary

This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with Chin Retrusion.

Conditions

  • Chin Retrusion

Interventions

DEVICE

Restylane Defyne

Intradermal injection

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Q-Med AB · Galderma R&D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2019-09-24
Completion
2020-09-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03597256 on ClinicalTrials.gov